1800-272-662
Shopping Cart 0
countryflagAU
Login

Viking Therapeutics Inc

Healthcare US VKTX

34.92USD
0.26(0.75%)

Last update at 2026-03-11T17:54:00Z

Day Range

33.9135.55
LowHigh

52 Week Range

8.2899.41
LowHigh

Fundamentals

  • Previous Close 34.66
  • Market Cap6973.35M
  • Volume2164931
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.92

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -85.89500M -68.86700M -54.99000M -39.49500M -25.77900M
Minority interest - - - - -
Net income -85.89500M -67.37900M -54.00200M -39.49500M -25.77900M
Selling general administrative 37.02M 16.12M 10.70M 10.73M 9.13M
Selling and marketing expenses 0.29M - - - -
Gross profit -0.29200M -0.29100M -0.29600M 0.01M -0.26000M
Reconciled depreciation 0.29M 0.29M 0.30M 0.28M 0.26M
Ebit -100.82700M -70.35500M -55.68200M -39.49500M -32.68700M
Ebitda -100.82700M -70.31300M -55.68900M 3.77M -25.52300M
Depreciation and amortization 0.29M 0.04M -0.00700M 3.81M 7.16M
Non operating income net other - 1.23M 0.69M 3.17M 6.91M
Operating income -100.82700M -70.35500M -55.68200M -42.66200M -32.68700M
Other operating expenses 100.83M 70.36M 55.68M 42.66M 32.69M
Interest expense 0.09M 1.49M 0.02M 0.11M 0.15M
Tax provision - - - - -
Interest income 11.05M 1.59M 0.70M 3.23M 7.05M
Net interest income 10.98M 1.53M 0.69M 3.13M 6.90M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -1.48800M -0.98800M -3.48400M -0.00400M
Total revenue 0.00000M 0.00000M 0.01M 0.01M 0.00000M
Total operating expenses 100.83M 70.36M 55.68M 42.66M 32.69M
Cost of revenue 0.29M 0.29M 0.30M 0.28M 0.26M
Total other income expense net 14.93M 1.49M 0.69M 42.62M 6.91M
Discontinued operations - - - - -
Net income from continuing ops -80.84900M -69.12500M -54.99000M -39.49500M -25.77900M
Net income applicable to common shares - -68.86700M -54.99000M -39.49500M -25.77900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 368.49M 168.53M 210.66M 256.50M 284.26M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.52M 3.41M 8.43M 7.72M 7.86M
Total liab 20.07M 23.21M 8.78M 12.16M 7.14M
Total stockholder equity 348.42M 145.32M 201.88M 244.34M 277.12M
Deferred long term liab - 0.04M 0.08M 0.05M 0.13M
Other current liab 11.30M 13.11M 7.30M 7.81M 4.04M
Common stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00100M
Capital stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00100M
Retained earnings -377.94400M -292.04900M -223.18200M -168.19200M -128.69700M
Other liab - - - - -
Good will - - - - -
Other assets - 0.07M 0.11M 0.40M 0.16M
Cash 55.52M 36.63M 26.37M 29.12M 8.38M
Cash and equivalents - - - - -
Total current liabilities 19.14M 21.95M 8.78M 12.13M 6.78M
Current deferred revenue - - - - -
Net debt -54.25600M -35.06800M -26.34200M -28.75800M -7.71500M
Short term debt 0.32M 0.30M 0.03M 0.33M 0.30M
Short long term debt - - - - -
Short long term debt total 1.26M 1.56M 0.03M 0.36M 0.66M
Other stockholder equity 726.75M 438.47M 425.61M 412.59M 405.80M
Property plant equipment - 1.42M 0.03M 0.32M 0.60M
Total current assets 367.23M 167.04M 210.53M 256.10M 283.50M
Long term investments - - - - -
Net tangible assets - 145.32M 201.88M 244.34M 277.12M
Short term investments 306.56M 118.85M 175.73M 219.27M 267.26M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 7.51M 8.53M 1.44M 3.99M 2.43M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.38900M -1.10200M -0.54900M -0.05400M 0.01M
Additional paid in capital - - - - -
Common stock total equity - 0.00100M 0.00100M 0.00100M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - -292.04900M -223.18200M -168.19200M -128.69700M
Treasury stock - -6.79500M - - -
Accumulated amortization - - - - -
Non currrent assets other 0.14M 0.07M 0.11M 0.08M 0.16M
Deferred long term asset charges - - - - -
Non current assets total 1.26M 1.49M 0.13M 0.40M 0.76M
Capital lease obligations 1.26M 1.56M 0.03M 0.36M 0.66M
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -207.55900M 54.75M 37.96M 41.57M 7.46M
Change to liabilities - 12.89M -3.05000M 5.32M 3.87M
Total cashflows from investing activities - 54.75M 37.96M 41.57M 7.46M
Net borrowings - - - - -
Total cash from financing activities 271.38M 4.16M 6.88M 0.95M 0.89M
Change to operating activities - 3.10M -0.38300M 6.16M -5.25500M
Net income -85.89500M -68.86700M -54.99000M -39.49500M -25.77900M
Change in cash 18.88M 10.26M -2.74600M 20.74M -16.40200M
Begin period cash flow 36.63M 26.37M 29.12M 8.38M 24.78M
End period cash flow 55.52M 36.63M 26.37M 29.12M 8.38M
Total cash from operating activities -73.37600M -48.39700M -47.58600M -21.77700M -24.75200M
Issuance of capital stock - - - - 0.00000M
Depreciation 0.29M 0.29M 0.30M 0.28M 0.26M
Other cashflows from investing activities - - - - 7.46M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - 0.00100M -
Sale purchase of stock -0.00712M -6.79500M -0.00071M -0.00030M -0.00015M
Other cashflows from financing activities -5.15200M 10.13M -0.70629M -0.29570M -0.15085M
Change to netincome - 8.67M 6.10M 5.82M 3.74M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - -2.31400M 0.45M 2.77M -7.05900M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 10.52M -2.74600M 20.74M -16.40200M
Change in working capital 3.55M 10.19M -2.92700M 7.72M -3.78300M
Stock based compensation 16.75M 8.67M 6.10M 5.82M 3.74M
Other non cash items 0.13M 1.32M 0.03M 0.14M 0.33M
Free cash flow -73.37600M -48.39700M -47.58600M -21.77700M -24.75200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
VKTX
Viking Therapeutics Inc		 0.26 0.75% 34.92 - - - 21.71 -71.6401
NVO
Novo Nordisk A/S		 0.05 0.13% 38.77 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.26 1.45% 491.91 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.47 0.84% 778.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics Inc

9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Brian Lian Ph.D. Pres, CEO & Director 1966
Mr. Gregory S. Zante Chief Financial Officer 1971
Ms. Marianne Mancini Chief Operating Officer 1965
Mr. Michael Morneau VP of Fin. & Admin. 1965
Dr. Brian Lian Ph.D. President, CEO & Director 1966
Mr. Michael Morneau Vice President of Finance & Administration 1965
Dr. Geoffrey E. Barker Ph.D. Senior Vice President of Pharmaceutical Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.